ReviewAdvances in pharmacology (San Diego, Calif.)2014
New directions in nicotine vaccine design and use.
Review in Advances in pharmacology (San Diego, Calif.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 100 citations in OpenAlex.
- An immunoinformatics approach for design and validation of multi-subunit vaccine againstJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Article
- Exploring computational approaches to design mRNA Vaccine against vaccinia and Mpox viruses.Immunity, inflammation and disease · 2024Article
- Multivalent Vaccination Strategies Protect against Exposure to Polydrug Opioid and Stimulant Mixtures in Mice and Rats.ACS pharmacology & translational science · 2024Article
- A viral vaccine design harnessing prior BCG immunization confers protection against Ebola virus.Frontiers in immunology · 2024Article
- A TLR7/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models.NPJ vaccines · 2023Article
- Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding.Structure (London, England : 1993) · 2023Article
- Immunotherapeutic strategies for treating opioid use disorder and overdose.Expert opinion on investigational drugs · 2023Review
- Multi Epitopic Peptide Based Vaccine Development Targeting Immobilization Antigen ofInternational journal of peptide research and therapeutics · 2023Article
- Formulation of Nanovaccines toward an Extended Immunity against Nicotine.ACS applied materials & interfaces · 2021Article
- Assessing Neutralized Nicotine Distribution Using Mice Vaccinated with the Mucosal Conjugate Nicotine Vaccine.Vaccines · 2021Article
- Tobacco Smoking and LiverJournal of oncology · 2021Review
- Attenuating nicotine's effects with high affinity human anti-nicotine monoclonal antibodies.PloS one · 2021Article
- Evaluation of the Immunogenic Response of a Novel Enterobactin Conjugate Vaccine in Chickens for the Production of Enterobactin-Specific Egg Yolk Antibodies.Frontiers in immunology · 2021Article
- Enhancement of a Heroin Vaccine through Hapten Deuteration.Journal of the American Chemical Society · 2020Article
- Improving immunogenicity and safety of flagellin as vaccine carrier by high-density display on virus-like particle surface.Biomaterials · 2020Article
- Modulation of immune responses using adjuvants to facilitate therapeutic vaccination.Immunological reviews · 2020Review
- Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity.Vaccine · 2020Article
- An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes.Parasites & vectors · 2020Article
- Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small "Non-Natural" Peptides.Molecules (Basel, Switzerland) · 2020Article
- Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders.NPJ vaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Clinical trials of nicotine vaccines suggest that they can enhance smoking cessation rates but do not reliably produce the consistently high serum antibody concentrations required. A wide array of next-generation strategies are being evaluated to enhance vaccine efficacy or provide antibody through other mechanisms. Protein conjugate vaccines may be improved by modifications of hapten or linker design or by optimizing hapten density. Conjugating hapten to viruslike particles or disrupted virus may allow exploitation of naturally occurring viral features associated with high immunogenicity. Conjugates that utilize different linker positions on nicotine can function as independent immunogens, so that using them in combination generates higher antibody concentrations than can be produced by a single immunogen. Nanoparticle vaccines, consisting of hapten, T cell help peptides, and adjuvants attached to a liposome or synthetic scaffold, are in the early stages of development. Nanoparticle vaccines offer the possibility of obtaining precise and consistent control of vaccine component stoichiometry and spacing and immunogen size and shape. Passive transfer of nicotine-specific monoclonal antibodies offers a greater control of antibody dose, the ability to give very high doses, and an immediate onset of action but is expensive and has a shorter duration of action than vaccines. Viral vector-mediated transfer of genes for antibody production can elicit high levels of antibody expression in animals and may present an alternative to vaccination or passive immunization if the long-term safety of this approach is confirmed. Next-generation immunotherapies are likely to be substantially more effective than first-generation vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.